Pure CT and CT/Cardiotoxin (CTC-310) formulations have been through 6 clinical investigations. The results of five of these studies have been published in scientific journals. The results from ...
Pure CT and CT/Cardiotoxin (CTC-310) formulations have been through 6 clinical investigations. The results of five of these studies have been published in scientific journals. The results from each condensed into table 1 and briefly summarized below. While CT is the principle active agent of interest the drug has been employed alone and in combination with CD, CD may allow the patient avoid the longer dose escalation phase of CT alone, and be more useful in subjects with advanced disease.. With that said, both products have been employed in human Phase I studies as listed in Table 2 & 3.
A phase I study was performed to evaluate the maximum tolerated dose (MTD), safety profile and pharmacokinetic data with CTC-310 (Costa et al., 1997). Fifteen patients with refractory malignancies were entered after providing written informed consent. CTC-310 was administered as an intramuscular injection daily for 30 consecutive days. Doses were escalated from 0.0025 to 0.023 mg/kg. Toxicities included local pain at the injection site, eosinophilia, reversible diplopia and palpebral ptosis. Dose escalation was stopped at 0.023 mg/kg, when two patients had developed anaphylactoid reactions. Both cases had high drug-specific IgG by EIA. MTD was 0.017 mg/kg and the recommended dose for phase II studies is 0.017 mg/kg. Stabilization was found in six patients.
From December 1996 to August 1997, five patients with histologic confirmed local advanced cancer (breast cancer 3, squamous cell cancer of the hand 1, chordoma 1) were treated at Bernardo Houssay Hospital, Oncology Unit with CTC-310, at the full dose of 0.014 mg/kg once a week, inoculated peritumorally and distributed into four different injections around the tumor, for no less than eight courses. All patients gave written informed consent according to local ethics committee requirements (Costa et al., 1998).
A complete response was observed in 3 pts (breast cancer 2, skin carcinoma of the hand 1), and a partial response was registered for the other two pts. The patient with local-advanced breast cancer (carcinoma en cuirasse) who was inoculated intra-and-peritumoral with CTC-310 for 6 weekly courses (0.014 mg/kg/week) with the drug had a >80% reduction in tumor. A 133 days follow-up demonstrated not only an objective complete response of the primary tumor mass, but the disappearance of supraclavicular tumor mass as well a significant reduction in lymphangitis. No toxicities were observed, except for a mild local pain at the site of the injection. It was concluded that weekly CTC-310 given by subcutaneous, peritumoral route is an active treatment for advanced skin metastatic tumors that is well tolerated and safe.
Phase I clinical trials of CT (Cura et al., 2002) was performed at the Hospital “General San Martìn” (Universidad Nacional de Rosario), Paranà, Entre Rìos. According to the protocol approved by the National Administration of Foods, Medicines and Medical Technology (A.N.M.A.T, Argentina), twenty six patients with solid tumours refractory to conventional therapy were admitted after signing a written informed consent. Twenty three patients were evaluated after the administration of CT as a daily intramuscular injection for 30 consecutive days (1-3 cycles) at doses from 0.03 to 0.22 mg.m-2. No drug-related deaths occurred in this study. Reversible (non-limiting) neuromuscular toxicity (Grades I to II) with diplopia and palpebral ptosis resulting from self-limited paresis of the external ocular muscles due to neuromuscular toxicity was the most characteristic side effect observed starting at the dose of 0.18 mg/m2.
Strabysmus and/or nystagmus appeared at 0.22 mg/m2. Patients complained by the discomfort during nystagmus episodes and no further increase in dose were considered. At the doses employed, neuromuscular toxicity did not impair the function of intrinsic ocular musculature and never extended to other muscular groups. No impairment of pharyngeal or laryngeal muscles was observed. Dysphonia, dysphagia, disartria or changes in FVC, suggesting drug related involvement of respiratory muscles were consistently absent (Cura et al., 2002). Neuromuscular toxicity did not require any dose adjustment and disappeared after one to three weeks even continuing the treatment. Except for transient increases (Grades I-III) in the levels of aminotransferases and creatinine kinase attributable to CT myotoxicity (Table III.1.3.1.5.2d), no other drug-related limiting toxicities were observed.
A Phase I clinical study with CT was completed at the George Pompidou Hospital (Paris, France). Titled as an “Open Label Phase I Clinical Trial of Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration,– designed to be conducted in two cohorts, cohort 1 was conducted with six patients (one male and five females) with advanced solid tumors and no further therapeutic options (Medioni et al, 2017). The primary objectives of the cohort 1 study was to; 1. Confirm that human subjects can be made tolerant to i.v. CT; 2. Assess the safety and tolerability of CT administered i.v. to Stage IV cancer patients using intra-patient dose escalation procedure; 3.Define Maximum Tolerated Dose (MTD) associated with intra-patient dose escalation. The secondary objectives of the study were to determine the frequency and titer of anti-CT antibodies, document any objective anti-tumour responses and assess if CT could affect analgesic activity: evaluated using questionnaire filled by patients during daily infusions.
Cohort dose escalation was planned once per week, with weekends off. Crotoxin was administered to subjects as out-patients daily by i.v. administration at the hospital over a 2-hour period by saline drip. Patients received Polaramine 10 mg i.v. (antihistamine) before CT administration and Ranitidine 50mg (anti-emetic) intravenously prior to treatment to minimize the potential for anaphylaxis. The escalation schedule extended over 54 days, with dose increased from 0.04 to 0.32 mg/m2. The patients were monitored daily at the clinic for the duration of the infusion (2 hours) and observed for 30 min following the infusion for adverse reactions. A total of 15 patients were screened and 6 were enrolled. Patients were treated with 8 cycles of Crotoxin administered i.v. over 2h daily, 5 days out of 7, with weekly intra-patient dose escalation. Dose escalation started at 0.04 mg/m2/day and the last dose was 0.32 mg/m2/day. Dose escalation extended over a period of 54 days (8 weeks).
For Serious Adverse Events (SAEs) unrelated to the study drug there were none in Patient 001, Patient 003 & Patient 004 (Medioni et al., 2018). Patient 002 experienced Anemia at dose level 6 (0.24 mg/m2/day) at day 37, grade 3, unrelated, reported as SAE, not reported as (Sudden Unexpected Serious Adverse Reaction (SUSAR), study drug was interrupted for 1 day. Patient 005 experience Hypoxia at dose level 5 (0.20 mg/m2/day) at day 29, grade 3, unrelated, reported as SAE, not reported as SUSAR. The study drug dose was not changed though treatment and hospitalization was required. Also, sepsis grade 4 and confusion grade 2 at dose level 5 (0.20 mg/m2/day) at day 35, unrelated, reported as SAE, not reported as SUSAR, patient died 2 days after stopping the study. Patient 006 also experienced Hypoxia at dose level at dose level 3 (0.12 mg/m2/day) at day 17, grade 2, unrelated, reported as SAE, not reported as SUSAR study drug dose not changed though treatment and hospitalization was required. Fever was reported at dose level 6 (0.24 mg/m2/day) at day 43, grade 1, unrelated, reported as SAE, not reported as SUSAR, study drug dose was interrupted for 1 day requiring treatment and hospitalization.
There were no reported SAEs or SUSARs related to the study drug. Adverse Events (AEs) related to the study drug were not reported in Subjects 002, 003 & 005. Diplopia and nystagmus were the most common. For those patients for whom pain was reported appeared to experience relief when CT was administered. The analgesic effect in all subjects appeared to dissipate during the weekends when no drug was being administered. The reported analgesic activity of Crotoxin in the Cura et al study (2002) was confirmed. All six patients presented Progressive Disease potentially due to the slow dose escalation protocol. It was established that intra-patient dose escalation of Crotoxin was safer than simple bolus administration.
Part 2 of the Phase I study was recently completed at the University Hospital Pitié-Salpêtrière (Paris, France). It followed design of Medioni et al (2017) in intra-patient dose escalation study to treat six patients (5 males and 1 female) with advanced solid tumours and no further treatment options: 1 nasal squamous cell carcinoma, 2 glioblastomas, 1 endometrial adenocarcinoma, 1 NSCLC and 1 prostatic carcinoma (Gil-Delgado et al., 2018). Lightweight Rythmic™ pump capable of continuous delivery (no weekend breaks) allowed patients to stay at home. Dose escalation from 0.08 to 0.64 mg/m2/day over 35 days and was carried on Mondays, Wednesdays and Fridays, followed by 2h observation at the clinic. Two of 6 patients developed possibly drug-related G1 diplopia and 1/6 pts increased ASAT/ALAT. One patient recruited with pre-existent diarrhoea syndrome with uncontrolled G2 hypomagnesaemia, G3 hypokalaemia and G2 anaemia, developed complete arrhythmia with asymptomatic atrial fibrillation that resolved with amiodarone. Patient was hospitalised for observation and the event was classified as a possible study drug-related SAE as well as related to the digestive syndrome and tubulopathy resulting from previous chemotherapy (nivolumab and platinum salts). It was concluded CT dose escalation is safe but too slow, doses achieved too low and too late for advanced pts. However, stable disease was observed in 2/6 patients and no DLT or MTD were reached.
Overall, of the 70 subjects recorded as having been treated with CT or CTC-310, 8 have had complete remissions, 13 had partial responses and 8 had stable disease. These outcomes were achieved in the absence of optimized treatment programs.
Close
